Blockchain Registration Transaction Record

Kamada Reports Stellar Q1 2025 Growth, Expands Plasma Operations

Kamada Ltd. reports 17% revenue growth in Q1 2025, driven by its diverse biopharmaceutical portfolio and strategic expansions, including a new plasma center.

Kamada's impressive Q1 performance and strategic expansions underscore its potential in the biopharmaceutical sector, particularly in treatments for rare diseases and plasma-derived therapies. For investors and stakeholders, Kamada's growth trajectory and innovative research initiatives present a compelling case for its role in addressing unmet medical needs, while its expansion in plasma collection could enhance supply chain resilience and industry collaboration.